克服基因靶向 T 细胞的毒性障碍。
Overcoming the toxicity hurdles of genetically targeted T cells.
机构信息
Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
出版信息
Cancer Immunol Immunother. 2015 Jan;64(1):123-30. doi: 10.1007/s00262-014-1641-9. Epub 2014 Dec 9.
Abstract
The recent successes of clinical trials with T cells genetically modified with either clonal T cell receptors or chimeric antigen receptors have also highlighted their potential toxicities. The aim of this focused review was to describe the adverse events observed in these clinical trials and to link them to the complex biology of genetically targeted T cells. Finally, strategies to overcome these toxicities will be proposed and discussed, including the use of suicide genes and other innovative gene therapy strategies.
摘要
最近，经过基因修饰的 T 细胞（使用克隆 T 细胞受体或嵌合抗原受体）的临床试验取得了成功，同时也凸显了其潜在的毒性。本次重点综述旨在描述这些临床试验中观察到的不良事件，并将其与基因靶向 T 细胞的复杂生物学联系起来。最后，将提出并讨论克服这些毒性的策略，包括使用自杀基因和其他创新的基因治疗策略。
相似文献
1
Overcoming the toxicity hurdles of genetically targeted T cells.
Cancer Immunol Immunother. 2015 Jan;64(1):123-30. doi: 10.1007/s00262-014-1641-9. Epub 2014 Dec 9.
2
Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
Semin Oncol. 2015 Aug;42(4):626-39. doi: 10.1053/j.seminoncol.2015.05.005. Epub 2015 Jun 12.
3
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11.
4
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Sci China Life Sci. 2016 Apr;59(4):340-8. doi: 10.1007/s11427-016-5027-4. Epub 2016 Mar 11.
5
Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Sci China Life Sci. 2016 Apr;59(4):349-59. doi: 10.1007/s11427-016-5034-5. Epub 2016 Mar 24.
6
Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.
Curr Pharm Des. 2018;24(1):78-83. doi: 10.2174/1381612824666171227222624.
7
Armed T cells with CAR for cancer immunotherapy.
Sci China Life Sci. 2016 Apr;59(4):331-2. doi: 10.1007/s11427-016-5047-0. Epub 2016 Apr 15.
8
Establishing guidelines for CAR-T cells: challenges and considerations.
Sci China Life Sci. 2016 Apr;59(4):333-9. doi: 10.1007/s11427-016-5026-5. Epub 2016 Mar 11.
9
Treating cancer with genetically engineered T cells.
Trends Biotechnol. 2011 Nov;29(11):550-7. doi: 10.1016/j.tibtech.2011.04.009. Epub 2011 Jun 12.
10
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):200-215. doi: 10.1016/j.bbcan.2018.01.005. Epub 2018 Jan 31.
引用本文的文献
1
FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma.
Cancer Gene Ther. 2024 Oct;31(10):1571-1584. doi: 10.1038/s41417-024-00823-2. Epub 2024 Aug 25.
2
Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity.
Elife. 2024 Jun 17;12:RP91999. doi: 10.7554/eLife.91999.
3
Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.
Clin Kidney J. 2024 Feb 20;17(3):sfae027. doi: 10.1093/ckj/sfae027. eCollection 2024 Mar.
4
Validation of a High-Sensitivity Assay for Detection of Chimeric Antigen Receptor T-Cell Vectors Using Low-Partition Digital PCR Technology.
J Mol Diagn. 2023 Sep;25(9):634-645. doi: 10.1016/j.jmoldx.2023.06.002. Epub 2023 Jun 16.
5
Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma.
Front Cell Dev Biol. 2022 Aug 26;10:941750. doi: 10.3389/fcell.2022.941750. eCollection 2022.
6
In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.
PLoS Comput Biol. 2022 Mar 18;18(3):e1009883. doi: 10.1371/journal.pcbi.1009883. eCollection 2022 Mar.
7
Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
Front Immunol. 2020 Nov 12;11:575609. doi: 10.3389/fimmu.2020.575609. eCollection 2020.
8
The Application of CAR-T Cells in Haematological Malignancies.
Arch Immunol Ther Exp (Warsz). 2020 Nov 6;68(6):34. doi: 10.1007/s00005-020-00599-x.
9
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview.
Cancers (Basel). 2020 Sep 9;12(9):2567. doi: 10.3390/cancers12092567.
10
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
Cell Commun Signal. 2020 Aug 25;18(1):134. doi: 10.1186/s12964-020-00617-7.
本文引用的文献
1
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.
Blood. 2014 Jun 19;123(25):3895-905. doi: 10.1182/blood-2014-01-551671. Epub 2014 Apr 21.
2
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4.
3
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170.
4
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.
Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27.
5
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
6
Toxicity management for patients receiving novel T-cell engaging therapies.
Curr Opin Pediatr. 2014 Feb;26(1):43-9. doi: 10.1097/MOP.0000000000000043.
7
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.
Sci Transl Med. 2013 Dec 11;5(215):215ra172. doi: 10.1126/scitranslmed.3006597.
8
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Immunol Rev. 2014 Jan;257(1):127-44. doi: 10.1111/imr.12139.
9
Design and development of therapies using chimeric antigen receptor-expressing T cells.
Immunol Rev. 2014 Jan;257(1):107-26. doi: 10.1111/imr.12131.
10
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.
Blood. 2013 Nov 14;122(20):3461-72. doi: 10.1182/blood-2013-04-493361. Epub 2013 Sep 9.
Zotero 插件